{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:08:14Z","timestamp":1759410494309},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T00:00:00Z","timestamp":1376611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0070866","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T21:08:19Z","timestamp":1376687299000},"page":"e70866","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Surface Antigen Seasonal Influenza Vaccine Produced in Mammalian Cell Culture and Administered to Young and Elderly Adults with and without A(H1N1) Pre-Vaccination"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01422512","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Micha","family":"Loebermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Voss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seetha","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Fritzsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Klammt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvius","family":"Frimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Riebold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil C.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,8,16]]},"reference":[{"key":"ref1","article-title":"Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999\u20132010","author":"P Hardelid","year":"2012","journal-title":"Influenza Other Respi Viruses"},{"key":"ref2","unstructured":"(2011) Annual epidemiological report. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stokholm: European Centre for Disease Prevention and Control (ECDC). Available: http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/1111_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf<\/ext-link>. Accessed: 8 Oct 2012."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/INF.0b013e31824bb179","article-title":"Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age","volume":"31","author":"T Vesikari","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1586\/erv.09.31","article-title":"Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines)","volume":"8","author":"A Doroshenko","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biologicals.2010.04.003","article-title":"Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine","volume":"38","author":"D Onions","year":"2010","journal-title":"Biologicals"},{"key":"ref6","unstructured":"CHMP (1997) Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. London: European Agency for the Evaluation of Medicinal Products (EMEA). CPMP\/BWP\/214\/96 CPMP\/BWP\/214\/96. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003945.pdf<\/ext-link>. Accessed: 18 Sep 2012."},{"key":"ref7","unstructured":"FDA (2007) Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. Bethesda, MD: Center for Biologics Evaluation and Research, Food and Drug Administration. Available: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074794.htm<\/ext-link>. Accessed: 9 Aug 2010."},{"key":"ref8","unstructured":"WHO (2011) Recommended composition of influenza virus vaccines for use in the 2011\u20132012 northern hemisphere influenza season. Available: http:\/\/www.who.int\/influenza\/vaccines\/2011_02_recommendation.pdf<\/ext-link>. Accessed: 12 Aug 2012."},{"key":"ref9","unstructured":"WHO (2010) Recommended viruses for influenza vaccines for use in the 2010\u20132011 northern hemisphere influenza season. World-Health-Organisation. Available: http:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/201002_Recommendation.pdf<\/ext-link>. Accessed: 1 Aug 2012."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.vaccine.2010.11.092","article-title":"Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study","volume":"29","author":"M Loebermann","year":"2011","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-2478(99)00171-6","article-title":"Preservative-free influenza vaccine","volume":"71","author":"A Banzhoff","year":"2000","journal-title":"Immunol Lett"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.vaccine.2009.11.043","article-title":"Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009\u20132010 Northern Hemisphere season","volume":"28","author":"IG Barr","year":"2010","journal-title":"Vaccine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1016\/j.vaccine.2008.03.075","article-title":"A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine","volume":"26","author":"JP Gregersen","year":"2008","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4161\/hv.19493","article-title":"Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons","volume":"8","author":"A Szymczakiewicz-Multanowska","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"ref15","first-page":"CD001269","article-title":"Vaccines for preventing influenza in healthy adults","volume":"7","author":"T Jefferson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older","volume":"200","author":"AR Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"ref17","article-title":"Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut\/Stand: Juli 2012","year":"2012","journal-title":"Epidemiol Bull"},{"key":"ref18","first-page":"8","article-title":"The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly","author":"P Blank","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e11601","DOI":"10.1371\/journal.pone.0011601","article-title":"Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA","volume":"5","author":"SM Zimmer","year":"2010","journal-title":"PLoS One"},{"key":"ref20","first-page":"17","article-title":"Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany","author":"J Cramer","year":"2012","journal-title":"Euro Surveill"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0070866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:17:08Z","timestamp":1540322228000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0070866"}},"subtitle":[],"editor":[{"given":"T. Mark","family":"Doherty","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,16]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0070866","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,16]]}}}